Sanara MedTech Q4 revenue $27.5M (+5% YoY); FY25 rev $103.1M (+19%); reaffirms FY26 guidance

Sanara MedTech Inc.

Net revenue Q4 2025 $27.5M (+5% YoY); excluding $1.8M prior-year BIASURGE hurricane sales, growth was 13%.
Full year 2025 net revenue $103.1M (+19% YoY); net loss from continuing ops narrowed to $0.4M from $1.9M.
Adjusted EBITDA improved to $4.7M (Q4) and $17.0M (FY), vs $4.1M and $9.1M in prior year.
Reaffirmed full year 2026 financial guidance; no specific numbers provided in the release.
BIASURGE received Vizient Innovative Technology contract effective Jan 1, 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sanara MedTech Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $27.5 million, net income Net loss from continuing operations of $1.1 million. Guidance reaffirmed.

Period: the fourth quarter and full year ended December 31, 2025
Revenue: $27.5 million
Net income: Net loss from continuing operations of $1.1 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

December 31, 2025, and reaffirmed its financial guidance for the full year ending December 31, 2026. Fourth Quarter 2025 Financial Summary (1 ) ● Net revenue increased 5% to $27.5 million, compared to $26.3 million in the fourth quarter of 2024. ○ As previously disclosed, the Company experienced growth in sales of BIASURGE ® Advanced Surgical Solution

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Sanara MedTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-012266

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.